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ABSTRACT
Protein phosphatase 2A (PP2A) plays an important role in the control of the cell 
cycle. We previously reported that the PP2A inhibitors, cantharidin and okadaic acid 
(OA), efficiently repressed the growth of cancer cells. In the present study, we found 
that PP2A inhibitors arrested the cell cycle at the G2 phase through a mechanism 
that was dependent on the JNK pathway. Microarrays further showed that PP2A 
inhibitors induced expression changes in multiple genes that participate in cell cycle 
transition. To verify whether these expression changes were executed in a PP2A-
dependent manner, we targeted the PP2A catalytic subunit (PP2Ac) using siRNA 
and evaluated gene expression with a microarray. After the cross comparison of 
these microarray data, we identified that CDK1 was potentially the same target when 
treated with either PP2A inhibitors or PP2Ac siRNA. In addition, we found that the 
down-regulation of CDK1 occurred in a JNK-dependent manner. Luciferase reporter 
gene assays demonstrated that repression of the transcription of CDK1 was executed 
through the JNK-dependent activation of the Sp1 transcription factor. By constructing 
deletion mutants of the CDK1 promoter and by using ChIP assays, we identified 
an element in the CDK1 promoter that responded to the JNK/Sp1 pathway after 
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stimulation with PP2A inhibitors. Cantharidin and OA also up-regulated the expression 
of p21, an inhibitor of CDK1, via autophagy rather than PP2A/JNK pathway. Thus, this 
present study found that the PP2A/JNK/Sp1/CDK1 pathway and the autophagy/p21 
pathway participated in G2/M cell cycle arrest triggered by PP2A inhibitors.
INTRODUCTION
Natural products and their derivatives have shown 
promising outcomes in cancer therapies. In our previous 
study, we demonstrated that cantharidin, the active 
constituent of Chinese blister beetle, [1] inhibited growth 
of pancreatic and breast cancer cells, [2, 3] offering 
a potential role for cantharidin in cancer treatment. 
Cantharidin acts as a potent and selective inhibitor of 
protein phosphatase 2A (PP2A), [4] a multimeric serine/
threonine phosphatase that is generally considered to be 
a cancer repressor. On one hand, inhibition of PP2A is 
believed to have tumor-promoting function [5] through 
induction of phosphorylation and activation of several 
substrate kinases, including IKK (IκB kinase), JNK 
(c-Jun N-terminal kinase), ERK (extracellular signal-
related kinase), p38, Akt, and PKC (protein kinase C), 
most of which accelerate growth. [6, 7] On the other hand, 
recent studies showed that PP2A inhibition by specific 
inhibitors also elicit growth-suppressive effect through 
several growth inhibition pathways, [8, 9] including the 
JNK pathway that we reported previously. [2] Inhibition 
of this pathway significantly reduced the cytotoxic effect 
of cantharidin and okadaic acid (OA; another classic PP2A 
inhibitor), [2] suggesting that inhibition of PP2A indeed 
has tumor suppressive function. Thus, understanding the 
molecular mechanism underlying the growth-suppressive 
effect of PP2A inhibition will not only minimize the 
unwanted side effect of PP2A inhibition but also facilitate 
the development of PP2A inhibitors (i.e., cantharidin) as 
new therapeutic agents for cancer treatment.
In our previous study, we found that treatment with 
PP2A inhibitors arrested G2/M cell cycle transition. [2] 
However, it remained unknown whether G2/M cell cycle 
arrest was induced through the JNK pathway dependent 
manner, and whether G2/M arrest is sufficient to suppress 
the growth of cancer cells. In the present study, we 
dissected the detailed signaling mechanisms involved in 
the G2/M cell cycle arrest and JNK dependent cell-killing 
effect induced by PP2A inhibitors in pancreatic, breast and 
lung cancer cells.
RESULTS
PP2A inhibitors repressed G2/M cell cycle 
transition
Dose- and time-dependent repression on cell growth 
by PP2A inhibitors was firstly confirmed by MTT assay. 
Pretreatment with SP600125, the classic JNK inhibitor, 
attenuated the growth repression by PP2A inhibitors, 
indicating the JNK pathway dependent cytotoxicity of 
PP2A inhibitors (Figure 1A and Supplementary Figure 1). 
In order to investigate whether G2/M cell cycle arrest was 
also executed through the activation of JNK pathway, 
we used flow cytometry, based on PI staining, to analyze 
the cell cycle distribution. As shown in Figure 1B, PP2A 
inhibitors induced cell accumulation at G2/M phase in a 
dose-dependent manner, with concurrent decreases in cell 
populations at G0/G1 and S phases, after 24 h treatment. 
The level of G2/M aggregation was reduced by pretreatment 
with SP600125, suggesting that PP2A inhibitors induced 
G2/M arrest through a JNK dependent pathway.
As flow cytometry analysis based on PI staining 
cannot distinguish between G2 and M cell cycle arrest, 
because cells at both these phases are diploid; flow 
cytometry analysis based on mithramycin A staining 
was performed. [10] Colchicine, an established M phase 
blocker, was used as the positive control for inducing 
M phase cell cycle arrest. As shown in Figure 1C, 
colchicine treated cells became round and detached; 
and flow cytometry analysis, based on mithramycin 
A staining, confirmed that the cells accumulated in M 
phase. Similarly, cells treated with PP2A inhibitors also 
became round and detached (Figure 1D). Furthermore, 
pretreatment with the JNK inhibitor, SP600125, protected 
cells from this morphological change; however, neither of 
these treatments induced accumulation of cells in M phase 
(Figure 1D), which suggested that G2/M cell cycle arrest 
induced by PP2A inhibitors occurred at G2 phase.
The cell cycle transition is regulated by cyclin, 
cyclin-dependent kinases (CDKs), and cyclin-dependent 
kinase inhibitors (CKIs). [11, 12] To investigate which 
genes were involved in the cell cycle alteration triggered 
by PP2A inhibitors, we performed microarray analyses to 
determine the mRNA expressions of 72 genes participating 
in cell cycle regulation. Among these genes, expression 
changes of 21 genes consist with the decreases in cell 
populations at G0/G1 and S phases, as well as arrested 
G2/M transition in both cantharidin and OA treated groups 
(Figure 1E), suggesting multiple genes were involved in 
the cell cycle regulation by PP2A inhibitors.
PP2A inhibitors repressed cell growth through 
JNK dependent downregulation of CDK1
Previous study proved that PP2A inhibitors also 
present an inhibition effect on PP1 (protein phosphatase 1). 
[13] To investigate whether these expression changes of 
cell cycle related genes were executed through a PP2A 
inhibition dependent manner, we applied siRNA targeting 
PP2A catalytic subunit α isoform (PP2Acα) [14] to get 
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a specific PP2A inhibition and tested mRNA expression 
profile by using microarray. Knockdown of PP2Acα was 
firstly confirmed by real-time PCR (Figure 2A). As α and 
β isoforms of PP2Ac share similar coding sequence, [15] 
we also tested the expression of PP2Acβ. As presented in 
Figure 2A, expression of PP2Acβ was also repressed by 
PP2Acα siRNA. By using primers targeting both α and 
β isoforms, we confirmed the knockdown of total PP2Ac 
expression (Figure 2A), which resulted in the down-
regulation of PP2Ac at protein level (Figure 2B).
Upon PP2Ac was knockdown, mRNA expression 
profile was evaluated by using microarray. The expression 
profiles upon treatment with PP2Acα siRNAs or PP2A 
inhibitors were pairwise compared. As shown in Figure 2C, 
Spearman’s rank correlation analysis revealed that the 
mRNA expression values correlated significantly, suggesting 
the changes of expression profiles upon PP2A inhibitor 
treatment were mainly through inhibition on PP2A.
After cross comparison of the expressions of cell 
cycle related genes upon treatment with PP2A inhbitors 
Figure 1: G2/M cell cycle arrest in PANC-1 cells after PP2A inhibitor treatment. A. Growth curve of cantharidin (CAN), 
and okadaic acid (OA) treated cells, with or without the pretreatment with JNK inhibitor, SP600125 (SP). **P < 0.01 vs. respective 
control groups; ##P < 0.01 vs. SP600125 group; &&P < 0.01 induction between groups. B. DNA histogram and cell cycle distribution after 
treatment with cantharidin and OA, pretreated with or without SP600125. C. Photomicrographs of Colchicine treated cells (×40); and flow 
cytometry analyses based on mithramycin A staining. D. Photomicrographs of PP2A inhibitors and JNK inhibitor-treated cells (×40); and 
flow cytometry analyses based on mithramycin A staining. E. Illustration of the microarrays results. Up-regulated genes were highlighted 
in red below, and down-regulated genes were highlighted in green below. The differences in expression changes reached more than 2-fold 
are marked with colored * (yellow, genes involved in the regulation of G1 phase and G1/S cell cycle transition; blue, genes involved in the 
regulation of S phase; red, genes involved in the regulation of G2 phase and G2/M cell cycle transition).
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and PP2Ac siRNAs, we identified that CDK1, the key 
regulator of G2/M cell cycle transition, [16] was the 
unique G2/M cell cycle regulator, which share the same 
tendence in all treated groups (Figure 2D and Figure 1E), 
suggesting the repression on CDK1 could be executed 
through PP2A inhibition dependent manner.
The down-regulation of CDK1 by PP2A inhibitor 
treatment was further confirmed at protein level by 
western blot (Figure 2E). To investigate the role of CDK1 
in PANC-1 cell cycle transition and cell growth, cells 
were treated with RO-3306, a CDK1 inhibitor, and cell 
cycle assay and MTT assay were performed. As shown 
Figure 2: Identification of CDK1 as the target gene at the downstream of PP2A/JNK pathway upon treatment with 
PP2A inhibitors in PANC-1 cells. A. and B. Confirmation of knockdown of PP2Ac by using real-time PCR (A) and western blot (B). 
C. Pairwise comparison of gene expression profiles upon treatments with cantharidin (CAN), OA and PP2Acα siRNAs by using spearman’s 
rank correlation analysis. D. Illustration of the microarrays results. E. Confirmation of down-regulated CDK1 upon treatment with PP2A 
inhibitors by using western blot. F. DNA histogram and cell cycle distribution after treatment with RO-3306. G. Growth curve of RO-3306 
treated cells. *P < 0.05, **P < 0.01 vs. control group. H. Growth curve of cantharidin, and OA treated PANC-1 cells, with or without 
the pretreatment with RO-3306. **P < 0.01 vs. respective control groups; ##P < 0.01 vs. RO-3306 group; &&P < 0.01 induction between 
groups. I. and J. After pretreatment with the JNK inhibitor, SP600125, for 3 h, PP2A inhibitors were added into the culture, and cells were 
treated for 24 h. (I) Real-time PCR and (J) Western blotting were used to evaluate mRNA levels and protein levels of CDK1, respectively.  
K. The effect of pretreatment with SP600125 shows no difference from cotreatment with RO-3306. **P < 0.01 vs. respective control groups;  
##P < 0.01 vs. RO-3306 group or SP600125 group; &&P < 0.01 induction between groups.
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in Figure 2F and 2G, RO-3306 dose-dependently arrested 
cell cycle in G2/M phase and repressed cell growth in both 
dose-and time-dependent manner, suggesting CDK1 plays 
an important role in PANC-1 cell growth. Furthermore, 
pretreatment with RO-3306 impaired the cytotoxicity of 
PP2A inhibitors (Figure 2H), suggesting CDK1 down-
regulation participated in the cytotoxicity induced by 
PP2A inhibitors.
To define the relationship between JNK pathway 
activation and CDK1 down-regulation, we pretreated cells 
with SP600125 and evaluated mRNA and protein levels 
of CDK1 upon treatment with PP2A inhibitors. As shown 
in Figure 2I, 2J and Supplementary Figure 2, the down-
regulation of CDK1 could be reversed by pretreatment 
with JNK inhibitor, suggesting that down-regulation 
of CDK1 was through a JNK dependent pathway. 
Pretreatment with RO-3306 impaired the protection 
effect of JNK inhibitor against the cytotoxicity of PP2A 
inhibitors (Figure 2K), suggesting the JNK pathway 
dependent growth inhibition and G2/M cell cycle arrest 
could be executed through down-regulation of CDK1.
Thus, the PP2A/JNK/CDK1 cell signaling transition 
pathway dependent G2/M cell cycle arrest could be 
involved in the mechanism of cytotoxicity induced by 
PP2A inhibitors.
PP2A inhibitors repressed CDK1 expression 
through activation of Sp1 transcriptional factor
To investigate the mechanisms involved in JNK 
dependent down-regulation of CDK1, we cloned the 
CDK1 promoter [17, 18] into the pGL3-Basic luciferase 
reporter vector and tested its transcriptional activity after 
PP2A inhibition. As shown in Figure 3A, treatment with 
PP2A inhibitors repressed the transcriptional activity of the 
CDK1 promoter. Conversely, repression was attenuated 
by pretreatment with SP600125, the JNK inhibitor, which 
suggested that JNK dependent down-regulation of CDK1 
was executed through repression of CDK1 transcription.
The transcriptional factor, Sp1, is a primary target of 
the JNK pathway; [19–24] therefore, we used luciferase 
reporter vectors containing the known Sp1 binding sites, 
GGGCGG or GGGGCGGGGC, to investigate whether 
Sp1 was involved in the JNK dependent down-regulation 
of CDK1. As shown in Figure 3B, Sp1 was activated after 
treatment with PP2A inhibitors; whereas pretreatment 
with SP600125 repressed Sp1 activation, indicating that 
PP2A inhibitors induced Sp1 activation through a JNK 
dependent pathway.
We next investigated whether repression of the 
CDK1 promoter, down-regulation of CDK1, and inhibition 
of cell growth, which were induced by PP2A inhibitors, 
were executed through Sp1 activation dependent manner. 
Real-time PCR using target specific siRNAs confirmed 
knockdown of Sp1 (Figure 3C). Luciferase reporter 
gene assays proved that interference of Sp1 attenuated 
repression of the CDK1 promoter (Figure 3D); real-time 
PCR confirmed down-regulation of CDK1 expression 
(Figure 3E); and MTT assays confirmed inhibition of cell 
growth (Figure 3F). These results suggested that PP2A 
inhibitors induced G2/M cell cycle arrest and repressed 
cell growth through the PP2A/JNK/Sp1/CDK1 pathway.
Identification of the CDK1 promoter region 
which responded to the PP2A/JNK/Sp1 pathway
Activated Sp1 can either be a transcriptional 
activator or a repressor, depending on the stimulation, 
cell type, and target DNA. [25] In this study, Sp1 acted 
as a transcriptional activator when bound to the known 
Sp1 binding sites, but behaved as a transcriptional 
repressor when bound to the CDK1 promoter; therefore 
we attempted to identify the region of the CDK1 promoter 
that responded to Sp1 when treated with PP2A inhibitors.
The CDK1 promoter deletion constructs used for the 
transient transfection analysis are illustrated in Figure 4A. 
A significant increase of luciferase activity was observed 
when the base pairs between -382 and -372 were deleted, 
suggesting this region might contain the element that 
responded to PP2A inhibitor treatment (Figure 4B). 
The JNK inhibitor had no influence on the change in 
transcriptional activity induced by PP2A inhibitors when 
this region (-382 to -372 bp) was deleted (Figure 4C); but 
attenuated transcriptional repression when this region was 
present (Figure 4D). This suggested that PP2A inhibitors 
decreased CDK1 transcription through JNK pathway 
dependent repression of the CDK1 promoter region 
between -382 and -372 bp.
ChIP assays were performed to confirm the binding 
of Sp1 to this promoter region. As shown in Figure 4E, 
binding of Sp1 to this region was increased by treatment 
with PP2A inhibitors, but attenuated by pretreatment 
with the JNK inhibitor, suggesting that JNK dependent 
repression of this promoter region was mediated through 
transcriptional factor Sp1. Because no known Sp1 binding 
sites were found in this region, this indicated indirect 
binding between Sp1 and this region.
PP2A inhibitors repressed cell growth through 
PP2A/JNK pathway independent and autophagy 
dependent up-regulation of p21
In our previous study, we have proved that expression 
of p21, the key inhibitor of CDK1, [11, 12] was upregulated 
upon treatment with PP2A inhibitors; [2] however, the 
mechanisms involved were unclear. By using microarray, 
we found that the down-regulation of p21 could be induced 
by cantharidin and OA (Figure 1E), but did not present 
when treated with PP2Acα siRNAs (Figure 2D), suggesting 
cantharidin and OA repressed p21 expression through a PP2A 
independent manner. To further verify whether activation 
of JNK pathway participated in the down-regulation of 
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Figure 3: Involvement of transcriptional factor Sp1 in the JNK/CDK1 dependent cytotoxicity of PP2A inhibitors against 
PANC-1 cells. A. Transcriptional activity of CDK1 promoter after treatment with PP2A inhibitors: after co-transfection with a reporter 
plasmid containing the CDK1 promoter and an internal plasmid; cells were pretreated with SP600125 for 3 h, followed by PP2A inhibitor 
treatment for 36 h; the cells were then harvested and luciferase reporter gene assays were performed. **P < 0.01 vs. respective control 
groups; ##P < 0.01 vs. SP600125 group; &&P < 0.01 induction between groups. B. Transcriptional activation of Sp1 by PP2A inhibitors: cells 
were first co-transfected with a reporter plasmid containing repeating Sp1 binding sites and an internal plasmid; cells were then pretreated 
with SP600125, followed by PP2A inhibitor treatment for 36 h before the luciferase reporter gene assays were performed. **P < 0.01 vs. 
respective control groups; #P < 0.05 and ##P < 0.01 vs. SP600125 group; &P < 0.05 induction between groups. C. Real-time PCR analysis of 
Sp1mRNA levels after transfection with Sp1-siRNA for 24 h. **P < 0.01 vs. control group. D. Knockdown of Sp1 attenuated repression of 
the CDK1 promoter: the reporter plasmid containing CDK1 promoter and the pRL-SV40 plasmid were co-transfected 24 h after transfection 
with Sp1-siRNA; cells were then treated with PP2A inhibitors for 36 h, followed by luciferase assay. E. Knockdown of Sp1 attenuated the 
downregulation of CDK1 expression: after transfection with Sp1-siRNA for 24 h, cells were treated with PP2A inhibitors for a further 24 h; 
CDK1 expression was evaluated by Real-time PCR. F. Knockdown of Sp1 attenuated the inhibition of cell growth: after transfection with 
Sp1-siRNA for 24 h, cells were treated with PP2A inhibitors for a further 24 h; cell viability was determined by MTT assay. **P < 0.01 vs. 
respective control groups; #P < 0.05 and ##P < 0.01 vs. Sp1-siRNA groups; &P < 0.05 and &&P < 0.01 induction between groups.
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p21, we pretreated cells with SP600125 and evaluated p21 
expression after treatment with cantharidin and OA. As 
shown in Figure 5A, 5B and Supplementary Figure 3, both 
the expression of p21 were up-regulated after PP2A inhibitor 
treatment; however, pretreatment with SP600125 had no 
repression on the level of up-regulation, suggesting that p21 
up-regulation was not through PP2A/JNK pathway.
In our previous study, we demonstrated that 
autophagy induction could arrest G2/M cell cycle transition 
through up-regulation of p21. [26] In the present study, we 
tried to investigate whether this mechanism could also be 
involved. By using the DsRed-LC3 reporter, the increased 
formation of LC3 punctate was observed following 
the treatment with cantharidin and OA (Figure 5C and 
Supplementary Figure 4), suggesting these reagents 
induces autophagy in cancer cells. Pretreatment with 3-MA 
(3-Methyladenine), a classic autophagy inhibitor, attenuated 
or even reversed the stimulation on p21 expression by OA 
and cantharidin (Figure 5D and Supplementary Figure 5), 
suggesting the increased p21 expression was executed 
through an autophagy dependent manner.
To find out whether the up-regulation of p21 
contributed to the cytotoxicity of cantharidin and OA, 
we used siRNA targeting p21 to block the p21 mediated 
effect on cell growth. Knockdown of p21 by siRNA was 
firstly confirmed by real-time PCR (Figure 5E). As shown 
in Figure 5F, knockdown of p21 impaired the repression 
on cell growth by cantharidin and OA, suggesting the 
Figure 4: Identification of the CDK1 promoter regions which responded to PP2A inhibitors in PANC-1 cells.  
A. Schematic diagram of the CDK1 promoter deletions created in the luciferase reporter construct, and the relative luciferase activities 
derived from the deletion constructs when transfected into PANC-1 cells. Cells were treated with PP2A inhibitors for 36 h after transfection 
and before the luciferase gene reporter assays were performed. The activity of the -276~+24 bp construct was given a value of 1, and the 
activities of the other transfections were normalized to this value. B. Sequence of the responsive element. C. JNK independent regulation 
of the activity of the -372~+24 bp construct; D. JNK dependent regulation of the activity of the -382~+24 bp construct, after treatment 
with PP2A inhibitors: after transfection, cells were treated with the JNK inhibitor for 3 h, and then treated with PP2A inhibitors for 36 h, 
followed by the luciferase gene reporter assays. E. JNK dependent regulation of binding between Sp1 and the responding element: cells 
were pretreated with SP600125 for 3 h, and then treated with PP2A inhibitors for 36 h, followed by the ChIP assays. *P < 0.05 and **P 
< 0.01 vs. respective control groups; #P < 0.05 and ##P < 0.01 vs. SP600125 group; &P < 0.05 and &&P < 0.01 induction between groups.
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autophagy dependent stimulation of p21 also participated 
in the cytotoxicity of cantharidin and OA.
DISCUSSION
JNK is a kinase that is evolutionarily conserved in 
eukaryotes. [27] In our previous studies, the JNK pathway 
was found to be overactivated by treatment with PP2A 
inhibitors, [2, 28] which led to JNK dependent repression 
of cell growth. [2, 28] In this study, we focused on cell 
cycle regulation by the JNK pathway, and proved that 
PP2A inhibitors arrested the cell cycle at G2 phase through 
a JNK dependent manner.
The specificity of PP2A inhibitors has always been 
questioned for its slight inhibition effect on PP1 [13]. 
By using microarray, we confirmed that cantharidin 
and OA share extremely similar effects on expression 
on target genes. By using Spearman’s rank correlation 
analysis, we found out that gene expression profiles of 
both cantharidin and OA were significantly correlated 
with PP2Ac knockdown groups. Thus, the present 
study proved the effects of PP2A inhibitors were 
mainly fulfilled through inhibition on PP2A, and both 
cantharidin and OA are reliable tools for investigation 
of PP2A. By using microarray, we identified that CDK1, 
the key regulator of G2/M cell cycle transition was 
Figure 5: Regulation of p21 expression by cantharidin and OA in PANC-1 cells. A. Real-time PCR and B. Western blotting 
were used to evaluate mRNA levels and protein levels of p21 after treatment with cantharidin or OA for 24 h, with or without pretreatment 
with SP600125. C. Formation of LC3 punctate after treatment with cantharidin or OA for 24 h. D. Real-time PCR was performed to 
evaluate mRNA levels of p21 after treatment with cantharidin or OA for 24 h, with or without pretreatment with 3-MA. E. Real-time PCR 
was used to confirm down-regulated mRNA levels of p21 after transfection with p21-siRNA for 24 h. F. After transfection with p21-siRNA 
for 24 h, PP2A inhibitors were added into the culture, and cells were treated cells for 48 h. Cell growth was evaluated by MTT assay. *P < 
0.05, **P < 0.01 vs. respective control groups; ##P < 0.01 vs. SP600125 group; &P < 0.05, &&P < 0.01 induction between groups. G. Cell 
signaling pathways involved in the present study.
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up-regulated by PP2A inhibitors or PP2Acα targeting 
siRNAs. For the first time, we have found that the 
expression of CDK1 could be regulated by JNK pathway, 
and that growth inhibition of PP2A inhibitors was 
through the JNK/CDK1 pathway.
Sp1 is a zinc finger transcription factor that belongs 
to the Sp/Kruppel-like factors (KLF) family, characterized 
by their affinity for GC-rich promoter sequences, and is a 
major downstream target of the JNK pathway. [19–24] Sp1 
has been shown to regulate the expression of thousands of 
genes involved in wide range of cellular processes, such 
as proliferation, growth, differentiation, and angiogenesis; 
[29, 30] therefore, we investigated whether the JNK 
dependent repression of CDK1 was mediated through Sp1. 
By using luciferase reporter gene assays, we demonstrated 
that PP2A inhibitors induced JNK upregulation of 
transcription at DNA sequences containing known Sp1 
binding sites. This indicated that Sp1 was activated 
through the PP2A/JNK pathway; however, transcription 
of CDK1 was also repressed, suggesting that regulation of 
Sp1 transcription was target specific.
Post-translational modifications of Sp1 have 
been implicated in the regulation of Sp1. For example, 
phosphorylation, glycosylation, sumoylation, acetylation, 
and ubiquitination regulate Sp1 stability in a proteasome-
dependent manner; [19, 31,–33] in addition, phosphorylation 
regulates the DNA binding and transcriptional activity of 
Sp1. [25] The following studies have proved that JNK plays 
an important role in the post-translational modification of 
Sp1: JNK activation is necessary to phosphorylate Sp1, 
[19, 23, 24] and to shield Sp1 from the ubiquitin-dependent 
degradation pathway; [19] knockdown or inhibition of JNK 
induced dephosphorylation resulted in the ubiquitination 
and degradation of Sp1; [19–23] phosphorylation of Sp1 
by JNK was found to promote DNA binding [34] and 
transcription in some studies, [24, 35] but repress DNA 
binding [23] in other studies. Interestingly, okadaic acid 
(OA) was found to increase the level of Sp1 phosphorylation 
[36–38] and prevent Sp1 degradation in a JNK dependent 
way; [39] in addition, OA induced phosphorylation of Sp1 
either promotes [38, 40] or represses [36] DNA binding, 
depending on the stimulation and target DNA. These data 
suggest that the post-translational modification of Sp1 may 
be involved in the transcriptional repression of CDK1 upon 
treatment with PP2A inhibitors.
Although no typical Sp1 binding sites were found 
in the DNA sequence that responded to the PP2A/
JNK pathway, ChIP assays confirmed the interaction 
between Sp1 and the responsive element of the CDK1 
promoter, which indicated indirect binding of Sp1 to this 
DNA region. A number of studies have demonstrated 
that post-translational modifications both regulate the 
intracellular compartmentalization of Sp1 and modulate 
its interactions with other transcription factors. [41–43] 
There are compelling data to indicate that the Sp1-
dependent activation and repression of target promoters 
is modulated by its interactions with a repertoire of 
heterogeneous transcriptional regulators. A partial list of 
Sp1-interacting proteins includes the Mediator complex, 
c-Myc, Ah, Arnt, ER, AR, GATAs, p53, MEF2C, 
Smad2-4, Msx1, Rb, NF-κB, NF-YA, VHL, MyoD, E2F, 
NFAT-1, and YY1; [41] however, which transcriptional 
regulator participated in the regulation of Sp1 in the 
responsive element of the CDK1 promoter remains to be 
verified.
Microarray data also indicated a PP2A independent 
regulation on p21 by cantharidin and OA. Consisting with 
this result, the PP2A inhibition dependent activation of 
JNK had no effect on p21 expression, although the basal 
activity of JNK represses p21 expression, which might 
promote mitosis. [28, 44] This data suggested that in the 
normal culture environment, JNK dependent repression 
on p21 promoted cell growth. While in the circumstance 
of treatment with PP2A inhibitors, overactivation of 
JNK inhibited cell growth through repression on CDK1 
(Figure 5G).
The PP2A/JNK independent repression on p21 
was further proved to be related to autophagy induction. 
Autophagy is a genetically programmed, evolutionarily 
conserved process that degrades long-living cellular 
proteins and organelles, including the endoplasmic 
reticulum, Golgi apparatus, and mitochondria. [45] 
During autophagy the cytoplasmic constituents are 
delivered to the lysosome, forming a double-membrane 
vesicle, termed as autophagosome. [46] There is 
an increasing interest in exploring autophagy as a 
mechanism of action in cancer therapy. By now, 16 
autophagy-related proteins (Atg proteins) have been 
identified to participate in autophagy. [47] LC3, the 
mammalian ontology of Atg8, is a credible marker 
for the autophagosome. [47, 48] During formation of 
autophagosomes, LC3 will form punctate structures 
within the cytoplasm that correspond to autophagic 
vesicles. [47]
Recent studies have explored the connection 
between PP2A and autophagy. PP2A can exert both a 
positive and negative effect on autophagy, depending on 
the particular step on which it acts and on its composition 
in subunits. [49] However, based on our present study, 
specific knockdown of PP2Ac did not affect the expression 
of p21. While treatment with cantharidin and OA 
stimulated p21 expression through autophagy dependent 
manner, suggesting the autophagy induced by cantharidin 
and OA might be executed through a PP2A inhibition 
independent manner.
In conclusion, our previous study had found that PP2A 
inhibitors activated the JNK pathway, induced G2/M cell 
cycle arrest, and inhibited growth in cancer cells. This study 
suggested that the PP2A/JNK/Sp1/CDK1 cell signaling 
pathway and autophagy/p21 pathway may be responsible 
for the G2/M cell cycle arrest and cytotoxicity by treatment 
with PP2A inhibitors in cancer cells (Figure 5G). These data 
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also explained the bidirectional mechanism of JNK regulation 
in cell proliferation: the basal activity of JNK accelerated 
proliferation through repression of p21; whereas, overactivated 
JNK repressed cell growth through upregulation of CDK1.
PP2A is always considered to be a cancer 
repressor. [5] Previous efforts mostly focused on up-
regulating PP2A to achieve an inhibition on its cancer 
promoting substrate kinases. [7] So it was really 
difficult to accept PP2A inhibitors in cancer treatment. 
Quite on the contrary, the dried body of mylabris, from 
which cantharidin is extracted, has been used as a 
traditional Chinese medicine for more than 2000 years 
and is still being used as a folk medicine. [1] Ancient 
Chinese applied this natural product to the treatment of 
cancer with the notion of “fighting fire with fire” [50] 
without awareness of its molecular target, PP2A. Thus, 
exploring the mechanism involved in the PP2A-inhibition 
dependent cytotoxicity, may bring new lights to cancer 
treatment. Our studies suggest that the PP2A/JNK 
pathway locates at the crossroad of determining cell fate. 
To maintain a normal cell function, the activity of PP2A/
JNK pathway must be restricted at an appropriate level, 
as both repression and overactivation on this pathway 
could result in growth inhibition. This phenomenon fits 
well with the ‘Yin-Yang’ theory, which is an ancient 
Chinese philosophy nowadays accepted around the world. 
[51, 52] The principle of Yin and Yang, the balance 
between opposing natural forces, has been emphasised 
as a fundamental property of cellular growth regulation. 
[52] Therefore, anti-cancer approaches through activation 
or repression on PP2A, could both be considered as 
disturbing the balance between Yin and Yang. And the 
bidirectional JNK transducts this signal, resulting in cell 
growth inhibition. Our investigations bring a new cancer 
treatment strategy by turning a cancer-promoting kinase 
into an anti-cancer kinase through inhibition of PP2A, 
providing a whole new way to fight cancer.
MATERIALS AND METHODS
Cell line and cultures
The human pancreatic cancer cell line 
PANC-1, breast cancer cell lines, T-47D and MCF-7, 
and lung cancer cell lines, NCI-H292 and NCI-H1650, 
were purchased from the American Type Culture 
Collection (ATCC, VA, USA). PANC-1 cells were 
maintained in Dulbecco’s minimum essential medium 
(DMEM; Gibco, NY, USA), while T-47D, MCF-7, 
NCI-H292 and NCI-H1650 cells were maintained in 
RPMI-1640 medium (Gibco), supplemented with 10% 
fetal calf serum (FCS; Hyclone, UT, USA), 100 units/
ml penicillin, and 100 mg/ml streptomycin. The cultures 
were incubated at 37°C in a humidified atmosphere with 
5% CO2. Cells were passaged every 2–3 days to obtain 
exponential growth.
Reagents
Cantharidin, okadaic acid (OA), SP600125, and RO-
3306 were purchased from Enzo Life Science International 
(PA, USA). 3-Methyladenine (3-MA) was purchased from 
Sigma (Sigma, MO, USA).
Cell cycle analysis (PI staining)
Cell cycle analysis using propidium iodide (PI) 
was performed as previously described. [2] Prior to 
treatment, cells were synchronized in the cell cycle by 
serum starvation for 24 h. [53] After treatment, the cells 
were fixed in 80% ice cold ethanol, and incubated with 
0.5% Triton X-100 solution containing 1 mg/ml RNase 
A at 37°C for 30 min. PI (Sigma) was added to a final 
concentration of 50 μg/ml followed by 30 min incubation 
in the dark. Cellular DNA content was analyzed by 
a fluorescence-activated cell sorter (FACS; Becton 
Dickinson, NJ, USA). Data were processed by ModFit LT 
software (Verity Software House, ME, USA).
Cell cycle analysis (mithramycin A staining)
Cell cycle analysis with mithramycin A was performed 
according to the protocol established by Schmidt et al. [10] 
Briefly, the cells were incubated with 0.1% nonidet P-40 
for 5 min, followed by fixation with 1% formaldehyde. 
Mithramycin A (Sigma) was added to the sample to a 
final contraction of 20 mg/ml. The green fluorescence of 
mithramycin A was analyzed by FACS (Becton Dickinson).
MTT assay
Cellular growth was evaluated by MTT (3-[4, 
5-dimethyltiazol-2-yl] 2, 5-diphenyl-tetrazolium bromide) 
assay. [54] Cells were seeded into 24-well tissue culture 
plates at 5 × 104 cells per well. After treatment, MTT 
(Sigma) was added to each well to a final concentration 
of 0.5 mg/ml, followed by incubation at 37°C for 4 h. The 
medium was then removed, and 600 μl of dimethyl sulfoxide 
(DMSO) was added per well. As the PP2A inhibitor-treated 
cells became detached, the formazana in the medium was 
harvested by centrifugation at 10, 000 rpm for 10 min, 
dissolved in 200 μl of DMSO, and then returned to the 
original well. The absorbance of total 800 μl formazana 
dissolved DMSO in each well was measured at 490 nm 
using a microplate ELISA reader (Bio-Rad Laboratories, 
CA, USA). The relative cell viability was calculated 
as follows: relative cell viability = (mean experimental 
absorbance/mean control absorbance) × 100%.
Real-time PCR
Total RNA was extracted using Trizol reagent 
(Invitrogen, CA, USA) according to the manufacturer’s 
protocol. After spectrophotometric quantification, 1 μg 
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total RNA in a final volume of 20 μl was used for reverse 
transcription with PrimeScript RT Reagent Kit (TaKaRa, 
Otsu, Shiga, Japan) according to the manufacturer’s protocol. 
Aliquots of cDNA corresponding to equal amounts of RNA 
were used for quantification of mRNA by real-time PCR 
using the LightCycler 96 Real-time Quantitative PCR 
Detection System (Roche, Indianapolis, IN, USA). The 
reaction system (25 μl) contained the corresponding cDNA, 
forward and reverse primers, and SYBR Green PCR master 
mix (Roche). All data were analyzed using B2M gene 
expression as an internal standard. The specific primers were 
as follows: (1) p21, forward, 5′-GGACCTGTCACTGTC 
TTGTACC-3′, reverse, 5′-TTCCTGTGGGCGGATT AG-3′, 
product, 177 bp; (2) CDK1, forward, 5′-CTAGAAAGTGAA 
GAGGAAGGGGTT-3′, reverse, 5′-CCATGTACTGACCAG 
GAGGGAT-3′, product, 193 bp; (3) Sp1, forward, 
5′-CAGTTGGCAGACTCTACA GC-3′, reverse, 
5′-TCATGTATTCCATCAC CACC-3′, product, 345 bp; 
(4) PP2Ac, forward, 5′-GTTCACCAAGGAGCTGGAC 
CA-3′, reverse, 5′-C ATGCACATCTCCACAGACAGT 
AAC-3′, product, 164 bp; (5) PP2Acα, forward, 
5′-CGCCAGAAGTACACGAGGAAC-3′, reverse, 5′-CGTT 
GGATTCTTTTGTCAGGATTT-3′, product, 240 bp; (6) 
PP2Acβ, forward, 5′-GGGAAACCTGCCTTTGTAT-3′, 
reverse, 5′-CATCATTAGTATGGCACATTTGGTC-3′, 
product, 156 bp; and (7) B2M, forward, 5′-TCAAGAA 
GGTGGTGAAGCAG-3′, reverse, 5′-AAGGTGGAGGAG 
TGGGTGTC-3′, product, 112 bp.
Transfection of small interfering RNA
Target specific small interfering RNAs 
(siRNAs) were designed and synthesized by 
Genepharma (Shanghai, China). The specific 
sequences were as follows: (1) Control-siRNA, sense, 
5′-UUCUCCGAACGUGUCACGUdTdT-3′, anti-sense, 
5′-ACGUGACACGUUCGGAGAAdT dT-3′; (2) p21- 
siRNA, sense, 5′-GACCAUGUGGACCUGUCACd 
TdT-3′, anti-sense, 5′-GUGACAGGUCCACAU GGUC 
dTdT-3′; (3) Sp1-siRNA-1, sense, 5′-CCAGCAACAUGG 
GAAUUAUdTdT-3′, anti-sense, 5′-AUAAUUCCCAUG 
UUGC UGGdTdT-3′; (4) Sp1-siRNA-2, sense, 5′-GCCGU 
UGGCUAUAGCAAAUdTdT-3′, anti-sense, 5′-AUUUGC 
UAUAGCCAACGGCdTdT-3′; (5) PP2Acα-siRNA-1, 
sense, 5′-CGUGCAAGAGGUUCGAUGUdTdT-3′, anti- 
sense, 5′-ACAUCGAACCUCUUGCACGdTdT-3′; (6) PP2 
Acα-siRNA-2, sense, 5′-GGCAGAUCUUCUGUCUA 
CAdTdT-3′, anti-sense, 5′-UGUAGACAGAAGAUCU 
GCCdTdT-3′. The transfections were performed with 
siRNA-Mate Transfection Reagent (Genepharma) 
according to the manufacturer’s protocol.
Western blot analysis
Rabbit anti-CDK1 was purchased from Cell 
Signaling Technology (MA, USA). Rabbit anti-p21, 
mouse anti-PP2Ac, and mouse anti-B2M antibodies were 
purchased from Santa Cruz Biotechnologies (Santa Cruz, 
CA, USA). Total protein was extracted using a lysis buffer 
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS, 1 mM EDTA, supplemented 
with protease inhibitors (10 mg/mL leupeptin, 10 
mg/mL aprotinin, 10 mg/mL pepstatin A, and 1 mM 
4-[2-aminoethyl] benzenesulfonyl fluoride). The protein 
extract was loaded onto an SDS-polyacrylamide gel, 
size-fractionated by electrophoresis, and then transferred 
to polyvinylidene fluoride (PVDF) membranes (Bio-
Rad Laboratories). After blocking in 5% non-fat milk 
for 1 h, the membranes were incubated overnight with 
primary antibodies at 4°C. The protein expression was 
determined using horseradish peroxidase-conjugated 
antibodies followed by enhanced chemiluminescence 
(ECL, Millipore, St Charles, MO, USA) detection. The 
intensity of the bands was captured by JS-1035 image 
analysis scanning system (Peiqing Science & Technology, 
Shanghai, China). B2M was used as the internal control.
Luciferase reporter gene plasmids
A series of deletion mutants of the human cdk1 
promoter [17, 18] spanning -2994 to +24 were generated by 
PCR using pairs of primers bearing specific restriction sites 
(Table 1), and subcloned into KpnI and XhoI sites of the 
pGL3-basic vector. The luciferase reporter plasmid, Sp1-
luc (1), which contains the sequence 5′-CGCGTGGGCGG 
AACTGGGCGG AGTTAGGGGCGG GA-3′, consisting 
of three consensus Sp1 binding sites (GGGCGG) from 
the SV40 promoter, was generated by subcloning the 
above fragment into the NheI and HindIII sites of the 
pGL3-basic vector, according to Sowa et al. [55] A 
further TransLucent Sp1 reporter [Sp1-Luc (2)], which 
contains the sequence 5′-ATTCGATCGGGGCGGGGC 
GAGATTAGATTCGATCGGGGCGGGGCGAG-3′, 
consisting of two consensus Sp1 binding sites 
(GGGGCGGGGC), was purchased from Panomics (CA, 
USA). The internal control plasmid, pRL-SV40, which 
contained the renilla luciferase gene was obtained from 
Promega (Madison, WI, USA).
Luciferase reporter gene assay
Cells were transiently co-transfected with the reporter 
plasmid (500 ng/well) and the internal control plasmid, pRL-
SV40 plasmid (100 ng/well) for 6 h using Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s protocol. 
The medium was renewed, and the treatments were 
initiated. After treatment, the cell lysates were subjected to 
the dual luciferase reporter assay (Promega) according to the 
manufacturer’s recommendations. The luciferase activities 
were measured using the GloMax-20/20 luminometer 
(Promega). The results were expressed as relative luciferase 
activity (the ratio of firefly luciferase activity to renilla 
luciferase activity).
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ChIP assay
ChIP assays were performed using the ChIP assay kit 
(Upstate Biotechnology, NY, USA) as previously described. 
[56] Briefly, Cells (1 × 107) were fixed in medium containing 
1% formaldehyde for 10 min at room temperature. After cell 
lysis, genomic DNA was sheared into 200–1000 bp fragments 
using Sonics VCX130 (Sonics & Materials, CT, USA). 
Sheared chromatin was incubated with anti-Sp1 or negative 
control IgG (Upstate Biotechnology) overnight at 4°C. NaCl 
was added to the ChIP samples for 4 h at 65°C to reverse 
the cross-links. To purify the immunoprecipitated DNA 
the following steps were performed: RNase and proteinase 
K were added in order; followed by phenol-chloroform 
extraction; ethanol precipitation; and resuspension of the 
DNA in distilled water. The purified DNA was further 
used as a template for real-time PCR detection using an 
ABI Prism 7500 sequence detection system (Applied 
Biosystems, CA, USA). The specific primers were as 
follows: forward, 5′-CCTTTACATTTTTGAGGCGGTC-3′, 
reverse, 5′-CTCCCAGCATTGGCACAGTT-3′, product, 
229 bp. Real-time PCR data were analyzed as previously 
described. [56]
Microarray assay
Sample preparation and processing procedure 
were performed as described in detail in the Agilent 
GeneChip Expression Analysis Manual (Santa Clara, 
CA). Differentially expressed genes were screened using 
Agilent 44K human whole-genome oligonucleotide 
microarrays. The selection criterion was defined as a 
more than 2-fold difference in the level of expression 
(difference in up-regulated expression more than 2-fold, 
and difference in down-regulated expression less than 
0.5-fold). Hierarchical clustering of samples was done by 
average linkage algorithm using TIGR MultiExperiment 
Viewer (The Institute for Genomic Research, Rockville, 
MD, USA).
Autophagy assay using the DsRed-LC3 reporter
To develop an autophagy reporter, we fused the 
LC3 (also known as ATG8) cDNA to the C terminus of 
DsRed as previously described. [57] To produce stable 
cell lines continuously reporting autophagy activity, 
recombinant lentiviruses expressing the DsRed-LC3 
reporter were generated and used to infect cells. The 
LC3 puncta were visualized with an Olympus BX51 
microscope (Tokyo, Japan). DNA was counterstained 
using DAPI (Sigma).
Statistical analysis
Each experiment was performed a minimum of three 
times. Results were expressed as the mean value ± standard 
deviation (SD). Statistical analysis was performed by 
unpaired Student’s t-test. The correlations between microarray 
assays were analyzed using Spearman's rank correlation 
analysis. A P value < 0.05 was considered significant.
Table 1: Sequences of the oligonucleotide pairs used by PCR to produce deletion mutants covering 
the CDK1 promoter. KpnI (GGTACC) and XhoI (CTCGAG) sites were added to the primers to direct 
subcloning, and are italicized and underlined. Positions of the DNA fragments relative to the transcription 
start site are indicated.
Position of DNA 
fragment
Sense 5′→3′ Anti-sense 5′→3′
–2994 to +24 ATGGTACCGATCTCCTGACAACGTGA CTTTGAAGCCAAGCTCGAGCAGTTT
–1935 to +24 ACGGTACCAGCGGTAACTGTATCTT CTTTGAAGCCAAGCTCGAGCAGTTT
–1578 to +24 ACAGCCTGGTACCCTAGAGCACTTC CTTTGAAGCCAAGCTCGAGCAGTTT
–1177 to +24 TGGATTGGTACCATGTCTAGCTCTGTTT CTTTGAAGCCAAGCTCGAGCAGTTT
–778 to +24 TTTAATGGTACCTAAGCCAGGCGTG CTTTGAAGCCAAGCTCGAGCAGTTT
–577 to +24 GCCGGTACCATAAACAAAATGTAAATA CTTTGAAGCCAAGCTCGAGCAGTTT
–465 to +24 GCGGTACCTTGAGTTTTCCATTTCCT CTTTGAAGCCAAGCTCGAGCAGTTT
–382 to +24 AAGGTACCTATACACTCCTAACCCTAAGT CTTTGAAGCCAAGCTCGAGCAGTTT
–372 to +24 CCGGTACCTAACCCTAAGTATTAGAAGT CTTTGAAGCCAAGCTCGAGCAGTTT
–351 to +24 TTGGTACCGAAAGTAATGGAATCTC CTTTGAAGCCAAGCTCGAGCAGTTT
–326 to +24 ATCTCGAGGTACCCACAATATCACTTT CTTTGAAGCCAAGCTCGAGCAGTTT
–301 to +24 AAACACAATATCACTTTTTTGGTACCTA CTTTGAAGCCAAGCTCGAGCAGTTT
–276 to +24 TTTGAACGGTACCAATGCTGGGAGAA CTTTGAAGCCAAGCTCGAGCAGTTT
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